Do you want to read an article? Please log in or register.
Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study
Breast Cancer
Related content
Breast Cancer
Neoadjuvant endocrine therapy often leads to breast and axilla-conserving surgery in stages II and III hormone receptor-positive breast cancer patients: A registry study
Int J Cancer
Andour L, Kroep JR, Putter H, Tollenaar RAEM, Mesker WE, Straver ME
doi: 10.1002/ijc.70219
Breast Cancer
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials
Lancet Oncol
Conforti F, Holtschmidt J, Nekljudova V, Sala I, Pagan E, Solbach C, Untch M, Denkert C, Bagnardi V, Pala L, Fasching PA, Schneeweiss A, Lück HJ, Viale G, De Pas T, van Mackelenbergh M, Huober J, Müller V, Link T, Karn T, Reinisch M, Marmé F, Bjelic-Radisic V, Schem C, Hartkopf A, Stickeler E, Hanusch C, Blohmer JU, Fehm T, Rhiem K, Gelber R, Loibl S
doi: 10.1016/S1470-2045(25)00546-7
Breast Cancer
Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients - Results from the prospective AXSANA registry trial
Eur J Cancer
Di Micco R, Hartmann S, Banys-Paluchowski M, de Boniface J, Schmidt E, Ditsch N, Stickeler E, Schroth J, Karadeniz Cakmak G, Hahn M, Thill M, Lux MP, Kolberg HC, Rubio IT, Gasparri ML, Kontos M, Bonci EA, Niinikoski L, Murawa D, Pinto D, Peintinger F, Schlichting E, Nina H, Valiyeva Qanimat H, Vanhoeij M, Rebaza L, Kadayaprath G, Porpiglia M, Gentilini OD, Kühn T, AXSANA Study Group
doi: 10.1016/j.ejca.2025.115607
Breast Cancer
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study
J Clin Oncol
Valenza C, Zheng Y, Milano M, Trapani D, Giordano E, Guidi L, Berton Giachetti PPM, Boldrini L, Castellano G, Katrini J, Malagutti B, Antonarelli G, Conforti F, Pagan E, Bagnardi V, Kirkner GJ, Sangalli C, Dibble KE, Colleoni M, Regan MM, Munzone E, Curigliano G, Partridge AH
doi: 10.1200/JCO-25-01660
RECOMMENDED
Breast Cancer
Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Cancer Treat Rev
Nakatani S, Hayashi T, Yamamoto K, Maeda H
doi: 10.1016/j.ctrv.2025.102923
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
SPECIAL REPORT
Breast Cancer
Managing Side Effects in Breast Cancer Treatment
Breast Cancer
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group
Lancet Oncol
Jensen MB, Torpe E, Teunissen Z, Taarnhøj G, Brix E, Knoop A, Yammeni S, Donskov F, Ejlertsen B
doi: 10.1016/S1470-2045(25)00085-3
Lung, Respiratory and Thoracic Cancer
Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study
Lung Cancer
Uprety D, Abrahami D, Marcum ZA, Li B, Sang A, Davis M, Rifi N, Kelton JM, Ramaswamy K, Sanghvi P, Bazhenova L
doi: 10.1016/j.lungcan.2025.108436